Picture of Celltrion Healthcare Co logo

091990 — Celltrion Healthcare Co News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareAdventurousLarge Cap

Brief: Celltrion's Regdanvimab Shows Strong Neutralising Activity Against Delta Variant In Animal Test

July 16 (Reuters) - Celltrion HealthCare Co Ltd  091990.KQ :
    * CELLTRION’S MONOCLONAL ANTIBODY TREATMENT FOR COVID-19,
REGDANVIMAB (CT-P59), DEMONSTRATES STRONG NEUTRALISING ACTIVITY
AGAINST DELTA VARIANT
    * CELLTRION GROUP - REGDANVIMAB (CT-P59) ALSO RETAINED ITS
NEUTRALISATION POTENCY AGAINST THE LAMBDA VARIANT USING A
PSEUDO-VIRUS NEUTRALISATION ASSAY
    * CELLTRION -  ANNOUNCES RESULTS FROM GLOBAL PHASE III
CLINICAL
TRIAL OF REGDANVIMAB (CT-P59) AT ECCMID 2021
    * CELLTRION - RESULTS SHOW 100% SURVIVAL RATE WITH VIRUS
ERADICATION FROM ALL ANIMALS TREATED WITH THERAPEUTIC DOSAGE OF
CT-P59

Source text for Eikon:  ID:nBw6vhWWwa 
Further company coverage:  091990.KQ 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Celltrion Healthcare Co

See all news